The trial results are critical, as it brings Eli Lilly's pill one step closer to becoming a new, needle-free alternative for ...

Novo Nordisk said yesterday that it’s licensed a new obesity drug from The United Laboratories, a Chinese drugmaker.

Hollywood has in recent years been undergoing a much-needed, long-awaited transformation in its portrayals of women and ...

For some people with a high risk of Alzheimer's who received a drug called gantenerumab for eight years, their risk of ...

It was only a matter of time until the GLP-1 receptor agonist drugs like Ozempic and Wegovy were superseded, and now it looks ...

Even with significant expansion in the global market for antibodies used in clinical care and research, scientists recognize that there is still untapped potential for finding new antibodies. Many ...

A new study funded by Eli Lilly reports that people without diabetes can lose up to 13% of their starting weight in 6 months ...

Discover why Eli Lilly and Company is set for a strong 2024 with a robust pipeline, solid financials, and strategic growth ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

the company's decision to construct new manufacturing sites in the U.S., creating thousands of jobs, indicates an aggressive expansion strategy. Such advances likely contributed to Eli Lilly's ...

The global anti-obesity drug market is expected to generate $12.8 billion in sales this year, and according to a new ... study after delivering excellent phase 2 data is unacceptable. Eli Lilly ...

Dr. Jitendra Singh, a renowned endocrinologist himself, emphasized the unique metabolic challenges faced by India due to its ...